Despite being one of the most controversial drugs in the United States as well as other parts of the world, cannabis is at the forefront of scientific studies aimed at discovering its relationship with psychiatric disorders.
As stated by the National Survey on Drug Use and Health conducted in 2015, about 22.2 million individuals had used cannabis just the previous month. This appears to corroborate the results of research performed by the World’s Psychiatric Institution that the use of cannabis during teenage years could lead to the development of schizophrenia in later years.
According to research published in The American Journal of Psychiatry, there is evidence that shows that cannabidiol which is one of the primary constituents of cannabis, has beneficial effects when used as adjunctive therapy for treating patients with schizophrenia.
Although the exact mechanism of the action of cannabidiol remains unclear, it seems that it doesn’t have any dire effects on dopamine receptors in the human brain. The research was led by Philip McGuire, FMedSci., of King’s College London.
The fact that people with schizophrenia have shown signs of clinical improvement in positive psychotic symptoms after undergoing treatment with cannabidiol is encouraging. Cannabidiol, which is a component of cannabis is believed to lessen the effect the THC (tetrahydro cannabidiol) as indicated by an industry-funded phase 2 research.
Research is still ongoing in a bid to establish how THC, the principal psychoactive compound present in cannabis affects people with schizophrenia. Nevertheless, cannabis continues to receive lots of attention for its use in the treatment and management of people with schizophrenia.